Skip to main content
SpringerLink
Log in

GM-CSF and Whole Cells

  • Reference work entry
  • First Online:
Cancer Therapeutic Targets

  • 1860 Accesses

Abstract

Granulocyte-macrophage colony stimulating factor (GM-CSF) is a pleiotropic cytokine critical to immune homeostasis, capable of both pro-inflammatory and tolerance-inducing properties. GM-CSF has a variety of current and potential clinical applications, including use as a growth factor for myeloid cell recovery after chemotherapy, as a cancer vaccine adjuvant, and in combinatorial immunotherapy with monoclonal antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 949.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.

    Article  CAS  PubMed  Google Scholar 

  • Ai WZ, Tibshirani R, Taidi B, et al. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood. 2009;113:5743–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein–based vaccine. J Clin Oncol. 2004;22:1916–25.

    Article  CAS  PubMed  Google Scholar 

  • Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27:3036–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533–44.

    Article  CAS  PubMed  Google Scholar 

  • Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci. 2009;106:15825–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci. 2008;105:3005–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014;321:1744–53.

    Article  Google Scholar 

  • Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008;222:287–98.

    Article  CAS  PubMed  Google Scholar 

  • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010a;363:411–22.

    Article  CAS  PubMed  Google Scholar 

  • Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010b;28:1099–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lawson DH, Lee S, Zhao F, et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015;33:4066–76.

    Google Scholar 

  • Levy R, Ganjoo KN, Leonard JP, et al. Active idiotypic vaccination versus control immunotherapy for folliculiar lymphoma. J Clin Oncol. 2014;32:1797–803.

    Google Scholar 

  • Madan R, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012. doi:10.1016/S1470-2045(12)70006-2. published online Feb 10, 2012.

    PubMed  Google Scholar 

  • Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer. 2010;10:425–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773–8.

    Article  CAS  PubMed  Google Scholar 

  • Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949–54.

    CAS  PubMed  Google Scholar 

  • Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–62.

    CAS  PubMed  Google Scholar 

  • Schuster SJ, Neepalu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29:2787–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Slingluff Jr CL, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016–26.

    Article  CAS  PubMed  Google Scholar 

  • Slingluff Jr CL, Petroni GR, Olson W, et al. Helper T-Cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26:4973–80.

    Article  PubMed  PubMed Central  Google Scholar 

  • Slingluff Jr CL, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671–7.

    Article  CAS  PubMed  Google Scholar 

  • Van den Eertwegh AJM, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012. doi:10.1016/S1470-2045(12)70007-4. published online Feb 10. 2012.

    PubMed  Google Scholar 

  • Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA, 2115, USA

    Glenn Dranoff

  2. Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 450 Brookline Avenue, Smith 353, Boston, MA, 02215, USA

    Kenneth F. May Jr.

Authors
  1. Glenn Dranoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth F. May Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenn Dranoff .

Editor information

Editors and Affiliations

  1. Division of Hematology & Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this entry

Cite this entry

Dranoff, G., May, K.F. (2017). GM-CSF and Whole Cells. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_37

Download citation

Publish with us

Policies and ethics

Search

Navigation